Loading patent…
AssigneeIndustry-University Cooperation Foundation Sogang University
InventorsYun-Jeong Heo, Yu-Rim Lee, Hyun-Hee Jung, You-Hee Cho
Estimating the term…
This invention relates to a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity to Pseudomonas aeruginosa, or a progeny bacteriophage thereof having a RFLP (Restriction fragment length polymorphism) DNA profile substantially equivalent to the bacteriophage MPK6. The present invention provides a bacteriophage MPK6 or a progeny bacteriophage thereof capable of treating a Pseudomonas aeruginosa infection disease, and suggests an anti-bacterial activity of MPK6 and its progeny bacteriophage using a mammalian and non-mammalian infection model. According to the present invention, the present bacteriophage MPK6 or progeny bacteriophage thereof represents very effective efficacy on treatment of P. aeruginosa-induced peritonitis-sepsis.
An isolated bacteriophage MPK6 as deposited with the Korean Culture Center of Microorganisms under Accession No. KCCM 11044P having a lytic activity to Pseudomonas aeruginosa.
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
From the US filing history. Foreign family members aren’t listed.
No references of this kind are recorded.
Involving viable microorganisms: testing for antimicrobial activity of a material
Microorganisms or materials therefrom: viruses; Subviral particles; Bacteriophages
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
Podoviridae: use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
About 3 years 4 months of term left · ends 9 Mar 2030 (estimated)
This application claims priority from Korean Patent Application No. 2009-0012659, filed on Feb. 17, 2009, the disclosure of which is incorporated herein by reference.
1. Technical Field
The present invention relates to a bacteriophage MPK6 and a progeny bacteriophage thereof, and a pharmaceutical composition for treating a Pseudomonas aeruginosa infection disease.
FIG. 1 represents transmission electron micrographs of MPK6 negatively stained with uranylacetate revealing their virion structure. Bar 100 nm.
FIG. 2 represents a plaque formation by MPK6 on various lipopolysaccharide (LPS) mutants. MPK6 phage lysates containing about 3×102 PFU were spotted onto the bacterial lawns of PAO1 (WT) and its congenic LPS mutants: rmd (A−B+core+), wbpM (A+B−core+), and rmlC(A−B−core−).
FIG. 3 shows a lytic activity of MPK6 in vitro. The PAO1 culture suspension were mixed with the phage lysate of MPK6 (▪) in LB at the MOI of 1 and then incubated further. The number of viable bacteria (CFU) was measured at appropriate dilutions to count about 102 CFU.
In one aspect of this invention, there is provided a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity to Pseudomonas aeruginosa, or a progeny bacteriophage thereof having a RFLP (Restriction fragment length polymorphism) DNA profile substantially equivalent to the bacteriophage MPK6.
In another aspect of this invention, there is provided a pharmaceutical composition for treating a Pseudomonas aeruginosa infection disease, comprising: (a) a therapeutically effective amount of the bacteriophage; and (b) a pharmaceutically acceptable carrier.
In still another aspect of this invention, there is provided a method for treating a Pseudomonas aeruginosa infection disease, which comprises administering to a subject the pharmaceutical composition comprising the bacteriophage.